Summary
This technical report discusses the advancements in bioconjugation technologies, particularly focusing on antibody-drug conjugates (ADCs). It outlines the challenges faced in the purification processes of ADCs and presents various novel technologies that enhance therapeutic efficacy. The report details the diversification of ADC formats and the emerging purification strategies necessary to address the complexities of modern bioconjugates. It describes the importance of site-specific conjugation and the increasing demand for chromatographic purification methods. The document also highlights the role of Lonza's Toolbox in providing scalable and robust solutions for bioconjugate development. Additionally, it presents case studies on purification strategies, including activated carbon filtration and chromatography methods, emphasizing the need for optimization in the manufacturing process. The report concludes with insights into the future landscape of bioconjugates, noting the significance of integrating purification processes into the overall development strategy to improve product quality while managing costs.
